ClinicalTrials.gg
CompletedNCT00389324Updated Apr 20, 2015Results posted

A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency

A Phase 2 interventional study of Immune Globulin Intravenous (Human) in Immunologic Deficiency Syndrome, sponsored by Grifols Therapeutics LLC. Completed at 8 sites in 2 countries. Open to participants aged 13 Years to 75 Years. Per ClinicalTrials.gov, last updated 2015-04-20.

Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
13 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 127 studies in Immunologic Deficiency Syndromes with a site in United States — 27 open to participants now, 34 under way, none of them phase 3. Immunologic Deficiency Syndromes · United States.

Enrollment
30th of 77
35 · median 28
Started
2006
with 4 others
Phase 2
27 of 127
2 open now
Registered
32nd of 127
by date
Lead sponsor
3 of 127
Grifols Therapeutics LLC

Among the 127 studies in Immunologic Deficiency Syndromes with a site in United States, this one is the 30th largest by enrollment of the 77 interventional ones that give a count, is one of 5 that started in 2006, is one of 27 in phase 2, and was the 32nd registered.

Immunologic Deficiency Syndromes

204 studies on the registry are indexed under Immunologic Deficiency Syndromes; 50 are open to participants now.

Browse Immunologic Deficiency Syndromes studies →

Open to participants now

27 of the 127 studies in Immunologic Deficiency Syndromes with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Immunologic Deficiency Syndromes studies recruiting now, 19 (44%) set no upper age limit and 14 (33%) stop at 75 or younger; 30 take children under 18; 10 take healthy volunteers.

This study: 13 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Immunologic Deficiency Syndromes with a site in United States, or all of them as a file.
02

Study summary

This study will compare the blood level of Gamunex in patients. Patients will take it as an injection under the skin or in a vein. The study will compare how safe and tolerable the two methods are in the patients. The patients in this study have a defect in their immune system from a genetic cause.

Read the detailed description

This is an open-label, single-sequence, multi-center trial with subjects previously diagnosed with primary immune deficiency. Subjects will be on IGIV until a steady state is reached at which time PK profiling during the IV phase will occur. Subjects will begin SC administration 1 week following last IV dose and followed for a period of six months. PK profiling in SC phase will occur when subject reaches approximate steady-state on SC administration.

03

Conditions studied

  • Immunologic Deficiency Syndrome

Keywords

  • Primary immune deficiency
04

Who can participate

Ages eligible
13 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults and adolescents (age 13-75 inclusive) with a documented and confirmed pre-existing diagnosis of chronic primary immunodeficiency
  • Previously or currently on IgG replacement therapy
  • Documented (within 3 months) plasma IgG level of ≥500 mg/dL on current IgG therapy (IgG level can be obtained at the screening visit if documentation is not available)
  • The medical records for all subjects within the previous 2 years should be available to document previous infections and treatment

Exclusion criteria

Exclusion Criteria:

  • Clinical evidence of any significant acute or chronic disease that, in the opinion of the investigator, may interfere with successful completion of the trial
  • The subject has a known adverse reaction to Gamunex or other blood products
  • The subject has a history of blistering skin disease, thrombocytopenia, bleeding disorder, diffuse rash, recurrent skin infections or other disorders where subcutaneous therapy would be
  • The subject has known selective IgA deficiency with the exception of a known selective IgA deficient subject who has no previous documented eventful reaction to products containing IgA
  • The subject is pregnant or lactating
  • The subject has significant proteinuria and/or has a history of acute renal failure and/or severe renal impairment (BUN or creatinine more than 2.5 times the ) and/or on dialysis
  • The subject has known substance or prescription drug abuse in the past 12 months
  • The subject has a history of or current diagnosis of deep venous thrombosis
  • The subject has an acquired medical condition that is known to cause secondary immune deficiency, such as chronic lymphocytic leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia ( less than 1000 x 10e6/L), or infection/AIDS
  • The subject is receiving any of the following medications: (long-term daily, >1 mg of prednisone equivalent/kg/day for >30 days) (intermittent courses would not exclude subject); ; or immunomodulators
  • The subject has non-controlled arterial hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg)
  • The subject has anemia ( \<10 g/dL) at screening
  • The subject has participated in another clinical trial within 30 days prior to screening (imaging studies without investigative treatments are permitted) or has received any blood product within the previous 3 months
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Immune Globulin Intravenous (Human)

    Immune Globulin Intravenous (Human), 10%, Caprylate/Chromatography Purified

    Biological: Immune Globulin Intravenous (Human)

Interventions

  • This trial was an open-label, single-sequence, study. The enrolled subjects received IGIV-C via two routes of administration (IV for 4 -5 weeks and SC for 24 weeks) in order to compare the PK variables, safety and tolerability of SC administration of IGIV-C. Certain subjects required IV IGIV-C dosing during a Run-in Phase (3 - 4 months) for steady-state conditions prior to the IV phase. Subjects received two IV infusions of IGIV (between 200 - 600 mg based on the subject's previous IgG dosing regimen, 3 to 4 weeks apart) until a steady-state was reached at which time PK profiling was performed. Subjects began weekly SC administration (1.37 times the weekly equivalency of each subject's monthly IV dose) 1 week following last IV dose and followed for a period of six months.

    Also known as: Gamunex, Gaminex, Immune globulin intravenous (Human)(IGIV), BAY 41-1000, TAL-05-00004, IGIV-C, IVIG, IGIVnex, NDC-13353-645-71, NDC-13353-646-24, NDC-13353-645-12, NDC-13353-645-15, NDC-13353-645-2

06

What researchers measure

Primary outcomes

  1. Geometric Least Square Means of Area Under the Curve (AUC) for Plasma Total Immunoglobulin G (IgG)

    Geometric least-squares mean of steady-state plasma concentration of total IgG vs. time profile (AUC).

    Time frame: IV Phase (21 or 28 days) at IV Visit #1, pre- and post-dose: 0 hr., 1 hr., and 1, 2, 3, 5, 7, 14, 21, and 28 days; SC Phase at Week #17, pre- and post-dose: 0 hr., and 1, 3, 4, 5, and 7 days

07

Results

Posted Dec 18, 2012

Participant flow

First Patient, First Visit: Nov. 21, 2006, Last patient, Last visit: Aug. 26, 2008. This study was performed at medical clinics.

Run-In Phase
Participant flow — Run-In Phase
MilestoneIGIV-C
Started21
Completed18
Not completed3
Withdrew: Adverse event1
Withdrew: Lost to follow-up1
Withdrew: Withdrawal by subject1
Intravenous Phase
Participant flow — Intravenous Phase
MilestoneIGIV-C
Started32
Completed32
Not completed0
Subcutaneous Phase
Participant flow — Subcutaneous Phase
MilestoneIGIV-C
Started32
Completed25
Not completed7
Withdrew: Adverse event2
Withdrew: Non-compliance with study medication2
Withdrew: Withdrawal by subject2
Withdrew: Lost to follow-up1

Outcome measures

PrimaryGeometric Least Square Means of Area Under the Curve (AUC) for Plasma Total Immunoglobulin G (IgG)

Geometric least-squares mean of steady-state plasma concentration of total IgG vs. time profile (AUC).

Time frame:
IV Phase (21 or 28 days) at IV Visit #1, pre- and post-dose: 0 hr., 1 hr., and 1, 2, 3, 5, 7, 14, 21, and 28 days; SC Phase at Week #17, pre- and post-dose: 0 hr., and 1, 3, 4, 5, and 7 days
Reported as:
Least squares mean · mg*hr/ml
Geometric Least Square Means of Area Under the Curve (AUC) for Plasma Total Immunoglobulin G (IgG)
mg*hr/mlGamunex Intravenous (IV) AdministrationGamunex Subcutaneous (SC) Administration
Geometric Least Square Means of Area Under the Curve (AUC) for Plasma Total Immunoglobulin G (IgG)7549 ± 12176706 ± 1241
Statistical analysis
  • Gamunex Intravenous (IV) Administration vs Gamunex Subcutaneous (SC) Administration · ANOVA · Geometric least square mean ratio: 0.888 · 90% CI 0.861 to 0.917An adjusted steady-state area under the concentration vs. time curve following SC administration based on IV dosing schedule was calculated as AUC0-τ,SC multiplied by 3 or 4 for subjects on every-3-week or every-4-week IV dosing schedule.

Adverse events

Collected over Run-in phase (if required): 3 - 4 months; Intravenous Phase: 4 - 5 weeks; Subcutaneous Phase: 24 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-In Phase—2/21 (9.5%)11/21 (52.4%)
Intravenous Phase—0/32 (0%)9/32 (28.1%)
Subcutaneous Phase—1/32 (3.1%)29/32 (90.6%)
Most frequent serious events
Most frequent serious events
EventRun-In PhaseIntravenous PhaseSubcutaneous Phase
PneumoniaInfections and infestations1/210/320/32
Sepsis syndromeInfections and infestations1/210/320/32
Incisional herniaInjury, poisoning and procedural complications1/210/320/32
Respiratory failureRespiratory, thoracic and mediastinal disorders1/210/320/32
Drug dependencePsychiatric disorders0/210/321/32
Most frequent other events
Showing 10 of 34
Most frequent other events
EventRun-In PhaseIntravenous PhaseSubcutaneous Phase
Infusion site erythemaGeneral disorders0/210/3213/32
Infusion site painGeneral disorders0/210/3213/32
Infusion site swellingGeneral disorders0/210/3211/32
SinusitisInfections and infestations2/210/328/32
Infusion site extravasationGeneral disorders0/210/328/32
Infusion site pruritusGeneral disorders0/210/328/32
Upper respiratory tract infectionInfections and infestations1/212/327/32
Infusion site bruisingGeneral disorders0/210/327/32
HeadacheNervous system disorders4/211/326/32
DiarrhoeaGastrointestinal disorders0/212/325/32

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Safety Population
<=18 years3
Between 18 and 65 years28
>=65 years4
Age, Continuous
Age, Continuous(years)Safety Population
Mean42.5 ± 15.8
Sex: Female, Male
Sex: Female, Male(Participants)Safety Population
Female28
Male7
Region of Enrollment
Region of Enrollment(participants)Safety Population
United States26
Canada9
08

Study locations

8 sites
  • University of California, Irvine
    Irvine, California 92697, United States
  • UCLA School of Medicine
    Los Angeles, California 90095, United States
  • Family Allergy & Asthma Center, PC
    Atlanta, Georgia 30342, United States
  • Allergy, Asthma & Immunology Associates, PC
    Omaha, Nebraska 68124, United States
  • Pediatric Allergy / Immunology Associates, PA
    Dallas, Texas 75230, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23219, United States
  • Dr. Donald F. Stark, Inc
    Vancouver, British Columbia V6H3K2, Canada
  • McGill University - Montreal General Hospital
    Montreal, Quebec H3G1A4, Canada
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Aug 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 4 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2006
First posted
Oct 18, 2006
Start
Nov 2006
Primary completionActual
Aug 2008
CompletionActual
Aug 2008
Results first posted
Dec 18, 2012
Last update
Apr 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00389324
Responsible party
Sponsor
First posted
Oct 18, 2006
Start date
Nov 2006
Primary completion
Aug 2008
Completion
Aug 2008
Results posted
Dec 18, 2012
Last update
Apr 20, 2015

Study contacts

Susan Sorrells
study director · Grifols Therapeutics LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion